Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data

  • Merck & Co Inc MRK announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative breast cancer (mTNBC). 
  • Keytruda combined with chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in OS.
  • The data were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.
  • A combination of Keytruda and chemotherapy reduced the risk of death by 27% over Chemo alone in previously untreated patients whose tumors expressed the PD-L1 biomarker at a combined positive score (CPS) of at least 10.
  • Adding Keytruda helped the patients live an additional 6.9 months or a median of 23 months versus 16.1 months in the Chemo alone group.
  • Keytruda snagged an accelerated approval in front-line triple-negative breast cancer in November. 
  • In July, an FDA green light for its use around surgery for early-stage, high-risk TNBC converted that conditional nod into a full one.
  • Related Link: FDA Approves Merck's Keytruda/Chemo Combo For Early Breast Cancer.
  • Price Action: MRK shares are down 0.95% at $71.00 during the premarket session on the last check Monday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralbreast cancerBriefsESMO21Phase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!